• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of February 20

Video

Here are the top 5 biosimilar articles for the week of February 20, 2023.

Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 20th, 2023.

Number 5: Alex Jung and Kim Dwyer, both members of the Midwest Business Group on Health (MBGH) board of directors, discussed why employers should be ready for the explosion of biosimilars entering the market, and how they can prepare.

Number 4: Fresenius Kabi announced the US launch of its pegfilgrastim biosimilar Stimufend (pegfilgrastim-fpgk), making it the fifth biosimilar referencing Neulasta to enter the market.

Number 3: In theory, by offering a lower-cost treatment option, biosimilars would help drive access for countless patients who simply could not afford the brand-name biologic. However, biosimilars have also encountered the harsh realities of the US health care system and its market forces.

Number 2: At the annual meeting of the Association for Accessible Medicines (Access 2023), Shark Tank’s Mark Cuban explained his dedication to and the inner workings of his online pharmacy that provides generic drugs to patients for significantly lower prices than traditional pharmacies.

Number 1: Biocon Biologics and its partner Viatris received a complete response letter (CRL) for their biosimilar referencing Avastin (bevacizumab), the second CRL for the companies in 2023. The news comes as Biocon publishes increased revenues for biosimilars and generics.

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Here are the top 5 biosimilar articles for the week of July 21, 2025.
Here are the top 5 biosimilar articles for the week of July 14, 2025.
Here are the top 5 biosimilar articles for the week of July 7, 2025.
Here are the top 5 biosimilar articles for the week of June 30, 2025.
Canavan & O’Dell
Here are the top 5 biosimilar articles for the week of June 23, 2025.
Here are the top 5 biosimilar articles for the week of June 16, 2025.
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Here are the top 5 biosimilar articles for the week of June 9, 2025.
Here are the top 5 biosimilar articles for the week of June 2, 2025.
Related Content
© 2025 MJH Life Sciences

All rights reserved.